In the EBLIS study, which MRD assay was employed?

In the EBLIS study, which MRD assay was employed?

• A. Precise MRD
• B. Signatera
• C. Guardant360
• D. CAPP-Seq

Answer: (B)

MRD detection in this context benefits from a tumor-informed approach that personalizes the assay to each patient’s cancer mutations. The EBLIS study used Signatera, a tumor-informed ctDNA MRD test. It starts by sequencing the patient’s tumor tissue to identify a set of patient-specific mutations. A personalized, targeted assay then monitors these exact mutations in serial blood samples, allowing highly sensitive detection of any residual disease after treatment and potentially identifying relapse earlier than imaging. This approach tends to be more sensitive for MRD than tumor-naïve panels that screen a fixed set of mutations across many patients, such as broad pretreatment profiling tests. While other methods like CAPP-Seq can be used for MRD, and broad panels like Guardant360 are useful for genomic profiling, they are not the tumor-informed, MRD-focused design used in this study. Precise MRD is not the platform employed here.

MRD detection in this context benefits from a tumor-informed approach that personalizes the assay to each patient’s cancer mutations. The EBLIS study used Signatera, a tumor-informed ctDNA MRD test. It starts by sequencing the patient’s tumor tissue to identify a set of patient-specific mutations. A personalized, targeted assay then monitors these exact mutations in serial blood samples, allowing highly sensitive detection of any residual disease after treatment and potentially identifying relapse earlier than imaging.

This approach tends to be more sensitive for MRD than tumor-naïve panels that screen a fixed set of mutations across many patients, such as broad pretreatment profiling tests. While other methods like CAPP-Seq can be used for MRD, and broad panels like Guardant360 are useful for genomic profiling, they are not the tumor-informed, MRD-focused design used in this study. Precise MRD is not the platform employed here.